CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
CRESCENT BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$12.36+0.52 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.4%
29M of 37M shares
Institutional holders
80
32 new, 12 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
2 buys · 16 sales
Net bought $29.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jiaqiang Li | 896,712 | 6.45% | 13G (passive) | Aug 13, 2025 |
| Invus Public Equities Advisors, LLC | 8,589,064 | 13.30% | 13G (passive) amendment | Dec 31, 2023 |
| Tang Capital Management, LLC | 700,000 | 5.04% | 13G (passive) | Oct 2, 2025 |
| Peter Harwin | 6,602,408 | 16.52% | 13D (active) amendment | Jul 16, 2026 |
| Peter Evan Harwin | 5,643,482 | 18.53% | 13D (active) amendment | Dec 4, 2025 |
| Abigail P. Johnson | 4,133,514 | 15.00% | 13G (passive) amendment | Dec 31, 2025 |
| Tomas Kiselak | 3,124,220 | 19.99% | 13D (active) | Jun 13, 2025 |
| Bong Y. Koh | 2,666,064 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| ForGrowth III PA B.V. | 1,677,852 | 6.10% | 13G (passive) | Dec 8, 2025 |
| Dames GP LLC | 1,662,917 | 6.03% | 13G (passive) amendment | Jun 30, 2026 |
| Bam Gp LLC | 1,510,033 | 5.48% | 13G (passive) | Mar 31, 2026 |
| Ryan Wilder | 1,500,000 | 5.40% | 13G (passive) | Dec 31, 2025 |
| 1Globe Capital LLC | 1,425,432 | 10.30% | 13G (passive) amendment | Oct 7, 2025 |
| FMR LLC | 1,414,190 | 10.20% | 13G (passive) | Jun 30, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. | 1,391,196 | 9.90% | 13G (passive) | Jun 13, 2025 |
| Bvf Inc/Il | 1,387,863 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,133,514 | 11.13% | $74.40M | – | 0.00% |
| Bvf Inc/Il | 2,748,763 | 7.40% | $49.48M | – | 1.27% |
| Fairmount Funds Management LLC | 2,747,866 | 7.40% | $49.46M | – | 3.27% |
| VR Adviser, LLC | 2,133,576 | 5.74% | $38.40M | – | 1.16% |
| Logos Global Management LP | 1,900,000 | 5.12% | $34.20M | +1,417,500 | 1.47% |
| Fcpm Iii Services B.V. | 1,677,852 | 4.52% | $30.20M | – | 4.02% |
| Balyasny Asset Management L.P. | 1,662,917 | 4.48% | $29.93M | +152,884 | 0.04% |
| Vestal Point Capital, LP | 1,630,000 | 4.39% | $29.34M | +130,000 | 0.69% |
| Opaleye Management Inc. | 1,319,351 | 3.55% | $23.75M | +6,736 | 2.15% |
| BlackRock, Inc. | 1,271,762 | 3.42% | $22.89M | +1,156,037 | 0.00% |
| Tang Capital Management LLC | 1,160,000 | 3.12% | $20.88M | – | 0.95% |
| Vanguard Capital Management LLC | 767,755 | 2.07% | $13.82M | −33,640 | 0.00% |
| Millennium Management LLC | 403,859 | 1.09% | $7.27M | +80,306 | 0.00% |
| Geode Capital Management, LLC | 384,576 | 1.04% | $6.92M | +280,355 | 0.00% |
| Jennison Associates LLC | 378,507 | 1.02% | $6.81M | +225,533 | 0.00% |
| Rtw Investments, LP | 372,856 | 1.00% | $6.71M | – | 0.06% |
| NEXTBio Capital Management LP | 372,856 | 1.00% | $6.71M | – | 3.09% |
| Remedium Capital Partners, LLC | 361,250 | 0.97% | $6.50M | New | 1.44% |
| State Street Corp | 315,587 | 0.85% | $5.68M | +276,520 | 0.00% |
| Ameriprise Financial Inc | 302,568 | 0.81% | $5.45M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 80 | 29M | 78.4% | 32 / 17 | 14 / 12 | 6M | 2M |
| Q1 2026 | 60 | 25M | 67.6% | 17 / 17 | 8 / 12 | 4M | 2M |
| Q4 2025 | 56 | 24M | 63.9% | 21 / 17 | 9 / 6 | 14M | 1M |
| Q3 2025 | 41 | 11M | 30.5% | 15 / 7 | 9 / 4 | 2M | 2M |
| Q2 2025 | 30 | 11M | 28.9% | 30 / 0 | 0 / 0 | 11M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 661,946 | 1.78% | $11.92M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 83,801 | 0.23% | $1.51M | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 28,660 | 0.08% | $414.71K | 0.01% | Jul 31, 2026 |
| Nuveen Equity Index Fund | 18,969 | 0.05% | $274.48K | 0.00% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 15,612 | 0.04% | $322.39K | 0.01% | May 31, 2026 |
| Vanguard Balanced Index Fund | 11,212 | 0.03% | $201.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 10,796 | 0.03% | $194.33K | 0.00% | Jun 30, 2026 |
| Global X Russell 2000 ETF | 10,277 | 0.03% | $148.71K | 0.01% | Jul 31, 2026 |
| Small Cap Index Fund | 10,253 | 0.03% | $184.55K | 0.01% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 2,503 | 0.01% | $36.22K | 0.00% | Jul 31, 2026 |
| SmallCap Growth Fund I | 1,862 | 0.01% | $26.94K | 0.00% | Jul 31, 2026 |
| Ultra Small Cap Profund | 278 | 0.00% | $4.02K | 0.01% | Jul 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 120 | 0.00% | $1.74K | 0.00% | Jul 31, 2026 |
| Profund Vp Ultra Small Cap | 89 | 0.00% | $1.60K | 0.01% | Jun 30, 2026 |
| Profund Vp Small Cap | 58 | 0.00% | $1.04K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua T. Brumm | Chief Executive Officer, Director | 271,765 | 0.73% | Sep 18, 2026 |
| Ellie Eunkyung Im | Chief Medical Officer | 21,446 | 0.06% | Sep 18, 2026 |
| Jan Pinkas | Chief Scientific Officer | 21,581 | 0.06% | Sep 18, 2026 |
| Jonathan McNeill | President and COO | 134,588 | 0.36% | Sep 18, 2026 |
| Richard William Scalzo | Chief Financial Officer | 19,730 | 0.05% | Sep 18, 2026 |
| Ryan Lynch | See Remarks | 13,631 | 0.04% | Sep 18, 2026 |
| Barbara Harlin Bispham | See Remarks | 18,710 | 0.05% | Sep 18, 2026 |
| Christopher Grant Doughty | Chief Business Officer | 62,194 | 0.17% | Dec 17, 2025 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 3,601,316 | 9.70% | Jul 20, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Jul 20, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Jul 20, 2026 |
| Peter Evan Harwin | Director, 10% owner | 2,747,866 | 7.40% | Jul 20, 2026 |
| David Charles Lubner | Director | – | – | Jun 3, 2026 |
| Susan Moran | Director | – | – | Jun 3, 2026 |
| Alexandra Balcom | Director | – | – | Jun 3, 2026 |
| Jonathan Violin | Director | 69,515 | 0.19% | Jun 3, 2026 |
| Ii Gp Llc Bvf | – | – | – | Jun 17, 2025 |
| Mark N. Lampert | 10% owner | – | – | Jun 17, 2025 |
| Value Fund Ii Lp Biotechnology | – | 2,955,440 | 7.96% | Jun 17, 2025 |
| I. Gp Llc Bvf | 10% owner | – | – | Jun 17, 2025 |
| Inc/Il Bvf | 10% owner | 4,980,812 | 13.41% | Jun 17, 2025 |
| Value Trading Fund OS LP Biotechnology | – | 1,644,624 | 4.43% | Jun 17, 2025 |
| Gp Holdings Llc Bvf | 10% owner | 707,116 | 1.90% | Jun 17, 2025 |
| Partners L. P/Il Bvf | 10% owner | – | – | Jun 17, 2025 |
| Value Fund L. P. Biotechnology | 10% owner | 2,265,606 | 6.10% | Jun 17, 2025 |
| Partners OS Ltd. BVF | – | – | – | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua T. Brumm Chief Executive Officer, Director | Sep 18, 2026 | Sale(10b5-1 plan) | −7,837 | $16.71 | $130.96K | 271,765 |
| Jonathan McNeill President and COO | Sep 18, 2026 | Sale(10b5-1 plan) | −3,839 | $16.71 | $64.15K | 134,588 |
| Barbara Harlin Bispham See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −620 | $17.90 | $11.10K | 18,710 |
| Joshua T. Brumm Chief Executive Officer, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −1,610 | $17.90 | $28.82K | 279,602 |
| Ellie Eunkyung Im Chief Medical Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −623 | $17.90 | $11.15K | 21,446 |
| Jan Pinkas Chief Scientific Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −658 | $17.90 | $11.78K | 21,581 |
| Ryan Lynch See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −240 | $17.90 | $4.30K | 13,631 |
| Richard William Scalzo Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −568 | $17.90 | $10.17K | 19,730 |
| Jonathan McNeill President and COO | Sep 16, 2026 | Sale(10b5-1 plan) | −731 | $17.90 | $13.08K | 138,427 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Jul 16, 2026 | Buy | +853,450 | $14.50 | $12.38M | 3,601,316 |
| Joshua T. Brumm Chief Executive Officer, Director | Jun 22, 2026 | Sale(10b5-1 plan) | −42,305 | $17.99 | $761.07K | 281,212 |
| Barbara Harlin Bispham See Remarks | Jun 22, 2026 | Sale(10b5-1 plan) | −1,218 | $17.99 | $21.91K | 19,330 |
| Ellie Eunkyung Im Chief Medical Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,219 | $17.99 | $21.93K | 22,069 |
| Ryan Lynch See Remarks | Jun 22, 2026 | Sale(10b5-1 plan) | −465 | $17.99 | $8.37K | 13,871 |
| Richard William Scalzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,112 | $17.99 | $20.00K | 20,298 |
| Jonathan McNeill President and COO | Jun 22, 2026 | Sale(10b5-1 plan) | −20,549 | $17.99 | $369.68K | 139,158 |
| Jan Pinkas Chief Scientific Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −1,288 | $17.99 | $23.17K | 22,239 |
| Jonathan McNeill President and COO | Dec 15, 2025 | Award | +6,000 | – | – | 159,707 |
| Jonathan McNeill President and COO | Dec 15, 2025 | Award | +19,507 | – | – | 153,707 |
| Ryan Lynch See Remarks | Dec 15, 2025 | Award | +4,000 | – | – | 12,378 |
| Ryan Lynch See Remarks | Dec 15, 2025 | Award | +8,378 | – | – | 8,378 |
| Richard William Scalzo Chief Financial Officer | Dec 15, 2025 | Award | +5,000 | – | – | 19,422 |
| Richard William Scalzo Chief Financial Officer | Dec 15, 2025 | Award | +14,422 | – | – | 14,422 |
| Joshua T. Brumm Chief Executive Officer, Director | Dec 15, 2025 | Award | +10,000 | – | – | 323,517 |
| Joshua T. Brumm Chief Executive Officer, Director | Dec 15, 2025 | Award | +45,117 | – | – | 313,517 |
| Christopher Grant Doughty Chief Business Officer | Dec 15, 2025 | Award | +8,000 | – | – | 62,194 |
| Christopher Grant Doughty Chief Business Officer | Dec 15, 2025 | Award | +14,714 | – | – | 54,194 |
| Ellie Eunkyung Im Chief Medical Officer | Dec 15, 2025 | Award | +16,298 | – | – | 16,298 |
| Ellie Eunkyung Im Chief Medical Officer | Dec 15, 2025 | Award | +5,000 | – | – | 21,298 |
| Barbara Harlin Bispham See Remarks | Dec 15, 2025 | Award | +12,422 | – | – | 12,422 |
| Barbara Harlin Bispham See Remarks | Dec 15, 2025 | Award | +6,000 | – | – | 18,422 |
| Jan Pinkas Chief Scientific Officer | Dec 15, 2025 | Award | +17,507 | – | – | 17,507 |
| Jan Pinkas Chief Scientific Officer | Dec 15, 2025 | Award | +5,000 | – | – | 22,507 |
| Peter Evan Harwin Director, 10% owner | Dec 4, 2025 | Buy | +1,360,000 | $13.41 | $18.24M | 2,747,866 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +657,308 | – | – | 707,116 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +556,617 | – | – | 593,740 |
| Gp Holdings Llc Bvf 10% owner | Jun 13, 2025 | Other | +56,079 | – | – | 62,383 |
| Siren, L.L.C. 10% owner | Aug 8, 2024 | Sale | −260,873 | $0.19 | $49.57K | 6,317,565 |
| Siren, L.L.C. 10% owner | Aug 7, 2024 | Sale | −61,488 | $0.18 | $11.07K | 6,578,438 |
| Invus Public Equities Advisors, LLC 10% owner | Aug 6, 2024 | Sale | −55,732 | $0.18 | $10.03K | 6,639,926 |
| Invus Public Equities Advisors, LLC 10% owner | Aug 5, 2024 | Sale | −164,523 | $0.19 | $31.26K | 6,695,658 |
| Siren, L.L.C. 10% owner | Aug 2, 2024 | Sale | −286,200 | $0.20 | $57.24K | 6,860,181 |
| Siren, L.L.C. 10% owner | Aug 1, 2024 | Sale | −63,564 | $0.22 | $13.98K | 7,146,381 |
| Siren, L.L.C. 10% owner | Jul 30, 2024 | Sale | −756,835 | $0.22 | $166.50K | 7,209,945 |
| Siren, L.L.C. 10% owner | Jul 29, 2024 | Sale | −363,949 | $0.24 | $87.35K | 7,966,780 |
| Siren, L.L.C. 10% owner | Jul 26, 2024 | Sale | −258,335 | $0.24 | $62.00K | 8,330,729 |
| Edwin Rock Chief Medical Officer | Jun 21, 2024 | Buy | +115,000 | $0.27 | $31.05K | 680,403 |
| Edwin Rock Chief Medical Officer | Jun 20, 2024 | Buy | +190,000 | $0.25 | $47.50K | 565,403 |
| Brian M. Hahn SVP Finance, CFO | Jun 18, 2024 | Buy | +17,500 | $0.25 | $4.38K | 70,643 |
| Mark Alan Goldberg Director | Mar 29, 2024 | Award | +4,584 | $3.00 | $13.75K | 24,828 |
| Daniel M. Junius Director | Mar 29, 2024 | Award | +5,209 | $3.00 | $15.63K | 98,459 |
| Rachel K. King Director | Mar 29, 2024 | Award | +3,334 | $3.00 | $10.00K | 515,194 |
| Mark Alan Goldberg Director | Dec 29, 2023 | Award | +5,827 | $2.36 | $13.75K | 20,244 |
| Patricia S. Andrews Director | Dec 29, 2023 | Award | +5,191 | $2.36 | $12.25K | 58,608 |
| Rachel K. King Director | Dec 29, 2023 | Award | +4,238 | $2.36 | $10.00K | 511,860 |
| Rachel K. King Director | Sep 30, 2023 | Award | +6,667 | $1.50 | $10.00K | 507,622 |
| Patricia S. Andrews Director | Sep 30, 2023 | Award | +8,167 | $1.50 | $12.25K | 53,417 |
| Mark Alan Goldberg Director | Sep 30, 2023 | Award | +9,167 | $1.50 | $13.75K | 14,417 |
| Edwin Rock Chief Medical Officer | Sep 22, 2023 | Buy | +30,403 | $1.38 | $41.96K | 375,403 |
| Edwin Rock Chief Medical Officer | Sep 21, 2023 | Buy | +35,000 | $1.38 | $48.30K | 345,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| T. Brumm Joshua Officer, Director | Sep 17, 2026 | 9,013 | $154.84K | Sep 18, 2026 | Restricted Stock Unit Vesting |
| McNeill Jonathan Officer | Sep 17, 2026 | 4,415 | $75.85K | Sep 18, 2026 | Restricted Stock Unit Vesting |
| McNeill Jonathan Officer | Sep 16, 2026 | 804 | $15.12K | Sep 16, 2026 | Restricted Stock Unit Vesting |
| T. Brumm Joshua Officer, Director | Sep 16, 2026 | 1,771 | $33.29K | Sep 16, 2026 | Restricted Stock Unit Vesting |
| Brian M. Hahn Officer | May 17, 2023 | 4,313 | $8.45K | May 17, 2023 | Stock Plan Activity |